Compare FLNT & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNT | PMVP |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.9M | 76.8M |
| IPO Year | 2009 | 2020 |
| Metric | FLNT | PMVP |
|---|---|---|
| Price | $2.93 | $1.15 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | 218.9K | ★ 250.6K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,764,000.00 | N/A |
| Revenue This Year | $5.89 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $0.96 |
| 52 Week High | $4.15 | $1.88 |
| Indicator | FLNT | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 63.28 | 43.29 |
| Support Level | $2.95 | $1.12 |
| Resistance Level | $3.60 | $1.26 |
| Average True Range (ATR) | 0.31 | 0.06 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 69.72 | 38.00 |
Fluent Inc is a commerce media solutions provider that connects brands with engaged consumers by leveraging diverse advertising inventory, robust first-party data, and proprietary machine learning. The company mainly delivers customer acquisition services through scalable digital marketing campaigns, linking advertisers with targeted audiences. It reaches consumers through its Commerce Media Solutions, which integrate targeted advertising into e-commerce and digital media transaction flows on partner websites and mobile applications, as well as through its owned and operated digital media properties. The company operates in the United States, which generates the majority of its revenue, along with international markets.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.